NovoCure Ltd.: Glioblastoma trials
The registry lists 10 Glioblastoma studies with NovoCure Ltd. as lead sponsor. 1 are open to participants now and 0 have results posted.
Phase 2 1Phase 3 3Phase 4 1No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- TTFields General Routine Clinical Care in ndGBM Patients: a French Prospective Non-Interventional Study (TIGER France)RecruitingNCT06924099
- EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed GlioblastomaActive, not recruitingNCT06556563Phase 3
- TIGER PRO-Active - Daily Activity, Sleep and Neurocognitive Functioning StudyStatus unknownNCT04717739
- Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBMCompletedNCT04492163Phase 2
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBMCompletedNCT04471844Not applicable
- TTFields Together With Temozolomide and Radiotherapy in Patients With Newly Diagnosed GBMStatus unknownNCT03780569Not applicable
- TTFields In GErmany in Routine Clinical CareStatus unknownNCT03258021
- Post-approval Study of NovoTTF-100A in Recurrent GBM PatientsTerminatedNCT01756729Phase 4
- Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)CompletedNCT00916409Phase 3
- Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)CompletedNCT00379470Phase 3